

NEW VENTURETEC

subject: **Press Release**
Date: November 12, 2008

For further information:
Peter Friedli
Neuhofstrasse 8
8834 Schindellegi
Tel: 044/283 29 00
Email: peter.friedli@friedlicorp.ch

New Venturetec: Results for the fiscal year 2007 / 2008 per September 30, 2008

Zürich, November 12, 2008. New Venturetec closed the fiscal year 07/08, ended September 30, 2008, with a loss of USD 5'571'379, compared with a profit of USD 11'066'671 in the fiscal year 06/07. The net asset value per share decreased from USD 26.18 to USD 25.07 which equals -4.1% during the reporting period; in CHF respectively from 30.45 to 28.18 or -7.4%. The share price in the same period decreased from CHF 21.25 to CHF 13.50, or -36.5%.

The net loss on investments for the reporting period is USD 3'377'534 compared to a gain of USD 17'814'627 in the same period 2007. The main reasons are write downs on the private portfolio companies Wstore, Iperia and Inflabloc and a decrease of the traded stock of Invenda. The main position, Osiris Therapeutics (NASDAQ: OSIR), increased its value by USD 26.2 million or 48.8% during the reporting period. Osiris represents as of September 30, 2008 54.5% of the total investment portfolio.

The operational progress of the portfolio companies is evident. As of September 30, 2008, New Venturetec held eight investments with four investments valued higher than the investment costs and four below investment costs. The net asset value is USD 125'325'829 compared to USD 118'000'000 paid in to New Venturetec since inception. This represents a total return on paid in capital of 6.2% as per September 31, 2008. The management fee earned in the reporting period was not paid, but rather accrued. USD 136'726 of the accrued management fee from 2003 was paid in the reporting period. The board remuneration for the outside board members for the reporting period was CHF 100'000.

The annual report, including financial statements for the reporting period can be downloaded from www.newventuretec.com.

New Venturetec is a publicly traded Swiss investment company (SIX: NEV) which invests directly in venture capital companies predominantly in the USA.

The Ordinary Shareholder Meeting takes place December 5, 2008 at the Hotel Park Hyatt, Beethovenstrasse 21, 8002 Zürich from 11.45 until 13.30. The following companies will present: mPortal and Osiris Therapeutics.